Craft

Albireo Pharma

Stock Price

$44.1

2023-03-02

Market Capitalization

$915.9 M

2023-03-02

Revenue

$40.6 M

FY, 2021

Albireo Pharma Summary

Company Summary

Overview
Albireo is an independent biotechnology company, which brings unique translational approaches to develop drugs that fulfil unmet medical needs in the gastrointestinal (GI) area. The team has a broad experience in drug development, primarily in the GI area and has an extensive network in the international scientific and clinical communities.
Type
Public
Status
Active
Founded
2003
HQ
Boston, MA, US | view all locations
Website
http://www.albireopharma.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

LocationsView all

2 locations detected

  • Boston, MA HQ

    United States

    10 Post Office Square #502

  • Göteborg, Västra Götalands län

    Sweden

    Arvid Wallgrens backe 20

Albireo Pharma Financials

Summary Financials

Revenue (Q3, 2022)
$9.8M
Gross profit (Q3, 2022)
$9.2M
Net income (Q3, 2022)
($37.8M)
Cash (Q3, 2022)
$222.5M
EBIT (Q3, 2022)
($34.7M)

Footer menu